COMMUNIQUÉS West-GlobeNewswire

Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

27/10/2018 - 03:18

Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension Findings presented at ASN Kidney Week 2018 SAN DIEGO, Oct. 26, 2018 (GLOBE NEWSWIRE) -- [...]

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2018

27/10/2018 - 00:30

TORONTO, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”) , a specialty cannabis company focused on the research, development and [...]

Helix BioPharma Corp. Announces Fiscal 2018 Year-End Results

26/10/2018 - 23:25

RICHMOND HILL, Ontario, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its [...]

The Ensign Group Schedules Third Quarter 2018 Earnings Call for Thursday, November 1, 2018

26/10/2018 - 22:15

MISSION VIEJO, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care [...]

Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018

26/10/2018 - 22:05

BOSTON, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline [...]

IntelGenx Announces Exercise of Over-Allotment Option

26/10/2018 - 22:02

SAINT LAURENT, Quebec, Oct. 26, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX) (OTCQX:IGXT) (the “ Company ” or “ IntelGenx ”) announces that in connection with its previously announced public offering [...]

Aduro Presents Preclinical Data for Anti-APRIL Antibody BION-1301 for the Treatment of IgA Nephropathy at ASN Kidney Week 2018

26/10/2018 - 22:01

BERKELEY, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data for its first-in-class anti-APRIL antibody BION-1301 supporting its use in the treatment of IgA [...]

Assurance Proves that an Engaging Work Culture Results in Happy Employees and a Great Place to Work

26/10/2018 - 18:59

SCHAUMBURG, Ill., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Assurance employees have a lot of praise about working at the insurance brokerage; praise that has landed the organization a win on the 100 Best Medium Workplaces list [...]

RadNet, Inc. Announces Date of its Third Quarter 2018 Financial Results Conference Call

26/10/2018 - 17:43

LOS ANGELES, Oct. 26, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]

Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference

26/10/2018 - 17:29

GAITHERSBURG, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer will provide a [...]

CRUZANI Snack Innovation: The MondoChurro!™

26/10/2018 - 16:30

Proprietary twist on a popular favorite by CRUZANI Oventa Foods ATLANTA, Oct. 26, 2018 (GLOBE NEWSWIRE) -- CRUZANI, Inc. (OTC: CZNI), www.CRUZANI.com , a global business development company focused on creating and [...]

New Clinical Trial Demonstrates Efficacy and Safety of Vayarin® Plus for Adults with ADHD

26/10/2018 - 16:14

COLUMBIA, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc, and leader in developing specialty nutrition and medical food products, announced today that a new clinical trial [...]

Orion Corporation: Managers' transactions - Eija Ronkainen

26/10/2018 - 16:01

ORION CORPORATION MANAGERS' TRANSACTIONS 26 OCTOBER 2018 at 17.00 EEST Orion Corporation: Managers' transactions - Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]

Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

26/10/2018 - 15:30

Late-Breaking Data Demonstrate Significant Association Between Higher ANAVEX®2-73 Concentration and Maintained Activities of Daily Living and Reduced Cognitive Decline in Alzheimer’s Disease Patients Data Confirm [...]

Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)

26/10/2018 - 15:15

Three- and four-year data continued to show reduction in amyloid plaque and to suggest a slowing of the rate of clinical decline in patients CAMBRIDGE, Mass., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and [...]

Neuralstem Announces $2.1 Million Registered Direct Offering

26/10/2018 - 15:00

GERMANTOWN, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, today announced that it has entered into [...]

Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018

26/10/2018 - 15:00

EMERYVILLE, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, [...]

Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin

26/10/2018 - 14:49

Bagsværd, Denmark, 26 October 2018 - Novo Nordisk today announced the headline results from PIONEER 8, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an [...]

CrownBio lance MuBase® 2.0, une base de données en libre accès de modèles murins en immuno-oncologie

26/10/2018 - 14:32

Les mises à jour mettent en valeur l'expérience d'utilisateur, fournissent des données complètes de caractérisation et ajoutent de nouveaux modèles SAN DIEGO, 26 oct. 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, société [...]